Disclosures for "Phase I Study of RAG-17, an siRNA Therapy Targeting SOD1, in Patients with SOD1-ALS: Preliminary Safety, Biomarker and Efficacy Data"
-
Prof. Wu has nothing to disclose.
-
Dr. Li has nothing to disclose.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Dr. Kang has nothing to disclose.
-
Dr. Li has stock in Ractigen Therapeutics. Dr. Li has received intellectual property interests from a discovery or technology relating to health care.
-
Author has nothing to disclose